Biogen Inc. Stock Price Decline

Biogen Inc., a prominent health care biotechnology company based in Cambridge, United States, has experienced a notable decline in its stock price. The company, which specializes in developing therapies for neurology, oncology, and immunology, has seen its stock price fall to $102.78 euros recently. This decline is significant when compared to its 52-week high of $238, achieved in July 2024. As of May 21, 2025, the stock price stands at $126.30, which is still a considerable drop from its 52-week low of $110.04 in April 2025.

Biogen Inc. operates in the health care sector, focusing on biotechnology, and is listed on the Nasdaq stock exchange. The company’s market capitalization is approximately $18.50 billion, with a price-to-earnings ratio of 10.85. The price-to-book ratio is currently 1.09, indicating the company’s valuation in relation to its book value.

The recent downturn in Biogen’s stock price reflects broader market dynamics and investor sentiment. Despite the challenges, Biogen continues to focus on its core areas of expertise, including therapies for multiple sclerosis, non-Hodgkin’s lymphoma, rheumatoid arthritis, Crohn’s disease, and psoriasis. For more detailed information about the company and its offerings, interested parties can visit their website at www.biogen.com .